In the STEP 1 trial extension, patients who lost an average of 17.3% of their body weight on semaglutide regained about two-thirds of that loss within a year of stopping the medication and lifestyle program (STEP 1 extension, PMC)
According to the World Health Organization (WHO), over 60 million people in Europe live with diabetes, while noncommunicable diseases account for nearly 90% of deaths in the region, driving increased demand for effective treatments such as GLP-1 receptor agonists
One of the most discussed classes of drugs in this category is GLP-1 receptor agonists, particularly Semaglutide, which is marketed under brand names such as Ozempic, Wegovy, and Rybelsus
General Health: A bad diet, smoking, or too much sun might compromise skin condition
We provide, medical doctors on staff, chiropractic treatments, soothing massage therapy, and physical therapy as well as diagnostics, including X-rays, all in-house under one roof